These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16014895)

  • 1. Lack of mutations in EGFR in gastroenteropancreatic neuroendocrine tumors.
    Gilbert JA; Lloyd RV; Ames MM
    N Engl J Med; 2005 Jul; 353(2):209-10. PubMed ID: 16014895
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
    Balak MN; Gong Y; Riely GJ; Somwar R; Li AR; Zakowski MF; Chiang A; Yang G; Ouerfelli O; Kris MG; Ladanyi M; Miller VA; Pao W
    Clin Cancer Res; 2006 Nov; 12(21):6494-501. PubMed ID: 17085664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.
    Takeuchi S; Yano S
    Respir Investig; 2014 Nov; 52(6):348-56. PubMed ID: 25453378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.
    Shih JY; Gow CH; Yang PC
    N Engl J Med; 2005 Jul; 353(2):207-8. PubMed ID: 16014893
    [No Abstract]   [Full Text] [Related]  

  • 5. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
    Kosaka T; Yatabe Y; Endoh H; Yoshida K; Hida T; Tsuboi M; Tada H; Kuwano H; Mitsudomi T
    Clin Cancer Res; 2006 Oct; 12(19):5764-9. PubMed ID: 17020982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA.
    Nakamura T; Sueoka-Aragane N; Iwanaga K; Sato A; Komiya K; Abe T; Ureshino N; Hayashi S; Hosomi T; Hirai M; Sueoka E; Kimura S
    J Thorac Oncol; 2011 Oct; 6(10):1639-48. PubMed ID: 21921847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the treatment of gastroenteropancreatic neuroendocrine tumors.
    Phan AT
    Clin Adv Hematol Oncol; 2014 Dec; 12(12 Suppl 19):3-5. PubMed ID: 25768101
    [No Abstract]   [Full Text] [Related]  

  • 8. Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor.
    Kuiper JL; Ronden MI; Becker A; Heideman DA; van Hengel P; Ylstra B; Thunnissen E; Smit EF
    J Clin Pathol; 2015 Apr; 68(4):320-1. PubMed ID: 25661795
    [No Abstract]   [Full Text] [Related]  

  • 9. Epigenetic changes in gastroenteropancreatic neuroendocrine tumours.
    Mapelli P; Aboagye EO; Stebbing J; Sharma R
    Oncogene; 2015 Aug; 34(34):4439-47. PubMed ID: 25435371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma.
    Genestreti G; de Biase D; Di Battista M; Cavallo G; Degli Esposti R; Visani M; Acquaviva G; Brand T; Pession A; Tallini G; Brandes AA
    Clin Lung Cancer; 2017 May; 18(3):e215-e217. PubMed ID: 28162944
    [No Abstract]   [Full Text] [Related]  

  • 11. Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations.
    Morabito A; Costanzo R; Rachiglio AM; Pasquale R; Sandomenico C; Franco R; Montanino A; De Lutio E; Rocco G; Normanno N
    J Thorac Oncol; 2013 Jul; 8(7):e59-60. PubMed ID: 23774386
    [No Abstract]   [Full Text] [Related]  

  • 12. Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non-small-cell lung cancer.
    Fujii A; Harada T; Iwama E; Ota K; Furuyama K; Ijichi K; Okamoto T; Okamoto I; Takayama K; Nakanishi Y
    Cancer Genet; 2015 May; 208(5):271-8. PubMed ID: 25682017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.
    Sequist LV; Haber DA; Lynch TJ
    Clin Cancer Res; 2005 Aug; 11(16):5668-70. PubMed ID: 16115901
    [No Abstract]   [Full Text] [Related]  

  • 14. Supersensitive mutation: two case reports of non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Myerson JS; Iqbal SA; O'Brien ME; Popat S
    Clin Lung Cancer; 2010 Sep; 11(5):E5-8. PubMed ID: 20837451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR tyrosine kinase domain mutations in human gliomas.
    Marie Y; Carpentier AF; Omuro AM; Sanson M; Thillet J; Hoang-Xuan K; Delattre JY
    Neurology; 2005 Apr; 64(8):1444-5. PubMed ID: 15851741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
    Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
    Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
    Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
    Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.
    He C; Zheng L; Xu Y; Liu M; Li Y; Xu J
    Clin Chim Acta; 2013 Oct; 425():119-24. PubMed ID: 23886554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Profiles and Current Therapeutic Agents in Neuroendocrine Neoplasms.
    Ohmoto A; Morizane C
    Curr Drug Targets; 2020; 21(4):389-405. PubMed ID: 31633473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.